Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00826228 · ClinicalTrials.gov registry record · Phase 4

Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)

A Phase 4 study of Spinal Cord Injury and Osteoporosis, sponsored by Thomas J. Schnitzer.

Completed
Registry status
Phase 4
Development phase
12
Enrollment target
1
Study location

NCT00826228 is a Phase 4 study of Spinal Cord Injury and Osteoporosis that has completed, run by Thomas J. Schnitzer. The registered enrollment target is 12 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00826228, a Phase 4 study of Spinal Cord Injury and Osteoporosis, has completed, sponsored by Thomas J. Schnitzer.

COMPLETED
Registry status
Phase 4
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Individuals with spinal cord injury sustain significant loss of bone mass in their lower extremities (20-40% or more). This study evaluates the ability of PTH and weight-bearing, two interventions that build bone, to increase bone mass in this population.

Interventions

  • DRUG teriparatide
  • OTHER weight-bearing

Study Locations (1)

Illinois

  • Rehabilitation Institute of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2009-06
Est. Completion 2012-12
Phase Phase 4

Sponsor

Thomas J. Schnitzer

5 total trials

What the Registry Record Tells You About NCT00826228

The ClinicalTrials.gov registry entry for NCT00826228 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (86% lower). The listed sponsor is Thomas J. Schnitzer, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Spinal Cord Injury appearing as the primary indexed condition, and to 2 interventions - of which teriparatide is the first listed.

NCT00826228 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00826228 about?

NCT00826228 is a clinical study titled "Effect of Parathyroid Hormone (PTH) and Weight-Bearing on Bone in Spinal Cord Injury (SCI)". Individuals with spinal cord injury sustain significant loss of bone mass in their lower extremities (20-40% or more). This study evaluates the ability of PTH and weight-bearing, two interventions that build bone, to increase bone mass in this population.

What is the current status of trial NCT00826228?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2009-06. Estimated completion is 2012-12.

What conditions does trial NCT00826228 study?

This clinical trial studies the following conditions: Spinal Cord Injury, Osteoporosis, Bone Loss.

What interventions are being tested in trial NCT00826228?

The interventions under investigation include: teriparatide (DRUG), weight-bearing (OTHER).

Who is sponsoring clinical trial NCT00826228?

This trial is sponsored by Thomas J. Schnitzer, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00826228 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injury

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.